| Trial ID # | NCT02659384; EORTC-1508 |
| Phase | II |
| Drug Class | Angiogenesis Inhibitors: VEGF |
| Drug Name | Bevacizumab |
| Alternate Drug Names | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin |
| Drugs in Trial | Acetylsalicylic acid, Atezolizumab, Bevacizumab |
| Eligible Participant | Platinum resistant ovarian cancer |
| Patients Enrolled | 122; 70% w/ prior bevacizumab |
| Therapy Setting | Recurrence |
| Study Design | Double Blind, Randomized |
| Endpoints | ORR, PFS, TFST, evaluated per RECIST |
| Efficacy | Bev vs Bev+Ate vs Bev+Ate+Asa: ORR: 24.1 vs 20.7 vs 27.6% |
| Clinically Significant Adverse Events | Bev vs Bev+Ate vs Bev+Ate+Asa: |
| Conclusion | The addition of atezolizumab to bevacizumab (with or without acetylsalicylic acid) improves PFS and TFST |
| Reference | Banerjee S et al. Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma. Annals Oncol (2021) 32 (suppl_5): abstract LBA32 |